Ivonescimab
生产企业：Akeso (康方生物), Summit Therapeutics
Ivonescimab (依沃西单抗, also known as AK112/SMT112) is a bispecific PD-1/VEGF antibody licensed from Akeso (康方生物) to Summit Therapeutics for development and commercialization in markets including the United States. Summit presented overall survival data from the HARMONi-6 trial at the ASCO 2026 Plenary session on May 31, 2026. An FDA PDUFA decision for ivonescimab in EGFR-mutated non-small cell lung cancer (NSCLC) is scheduled for November 14, 2026. Much of the clinical data supporting the filing has been generated from studies conducted in China, raising questions about translatability to Western patient populations.
Ivonescimab (依沃西单抗, also known as AK112/SMT112) is a bispecific PD-1/VEGF antibody licensed from Akeso (康方生物) to Summit Therapeutics for development and commercialization in markets including the United States. Summit presented overall survival data from the HARMONi-6 trial at the ASCO 2026 Plenary session on May 31, 2026. An FDA PDUFA decision for ivonescimab in EGFR-mutated non-small cell lung cancer (NSCLC) is scheduled for November 14, 2026. Much of the clinical data supporting the filing has been generated from studies conducted in China, raising questions about translatability to Western patient populations.
Ivonescimab is a first-in-class bispecific antibody that simultaneously targets programmed death-1 (PD-1) and vascular endothelial growth factor (VEGF), functioning as a dual immune checkpoint inhibitor and anti-angiogenic agent.
本品联合培美曲塞和卡铂，用于经表皮生长因子受体（EGFR）酪氨酸激酶抑制剂（TKI）治疗后进展的EGFR基因突变阳性的局部晚期或转移性非鳞状非小细胞肺癌（NSCLC）患者的治疗。
共 1 项相关疾病
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
